`2009 – February 2015
`
`Sales Dollars ($MM)
`VIMPAT®
`Total Branded
`Total Generic
`
`Prescriptions (000's)
`VIMPAT®
`Total Branded
`Total Generic
`
`Sales per Prescription
`VIMPAT®
`Total Branded
`Total Generic
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`$35.5
`$1,766.9
`$587.4
`
`83.6
`7,411.8
`16,733.8
`
`$424.63
`$238.39
`$35.10
`
`$135.8
`$1,462.4
`$529.1
`
`312.0
`5,033.3
`19,128.3
`
`$435.32
`$290.54
`$27.66
`
`$227.5
`$1,514.4
`$529.5
`
`502.3
`4,631.9
`20,133.0
`
`$452.92
`$326.95
`$26.30
`
`$338.6
`$1,592.9
`$481.7
`
`659.6
`4,115.4
`21,386.0
`
`$513.33
`$387.06
`$22.52
`
`$475.2
`$1,732.2
`$664.0
`
`819.7
`3,648.2
`23,148.7
`
`$579.70
`$474.79
`$28.69
`
`$629.0
`$2,025.7
`$744.0
`
`972.6
`3,585.3
`24,560.6
`
`$646.74
`$564.98
`$30.29
`
`Jan–Feb
`2015
`
`Total
`
`$114.9
`$360.8
`$121.6
`
`$1,956.5
`$10,455.1
`$3,657.3
`
`171.8
`574.5
`4,023.0
`
`3,521.6
`29,000.5
`129,113.4
`
`$668.86
`$627.91
`$30.24
`
`$555.58
`$360.52
`$28.33
`
`Notes:
`I understand from counsel that UCB’s standard business practice for evaluating the performance of VIMPAT® in the AED marketplace is to "factor" sales
`information related to certain AEDs to determine dollar sales that are associated with epilepsy.
`VIMPAT® launched May 2009.
`
`Sources:
`Sales Dollars ($MM): Ex. 2176, p. 4 (IMS)
`Prescriptions (000s): Ex. 2171, p. 4 (IMS)
`
`Page 1 of 1
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2178 - 1/1